Publications

  1. Vaughan LE, Schulte PJ, Knauf F, Sas DJ, Milliner DS, Lieske JC. Urine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1. Am J Kidney Dis. 2026 Jan; 87 (1):138-140 Epub 2025 Sept 20
    View PubMed
  2. Lieske JC, Groothoff JW, Frishberg Y, Garrelfs SF, Milliner DS, Magen D, Sellier-Leclerc AL, Shasha-Lavsky H, Bakkaloglu S, Lemoine S, Fuster DG, Devresse A, Cytter-Kuint R, Kajbaf F, Du W, Gansner JM. Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study. Kidney Med. 2025 Nov; 7 (11):101115 Epub 2025 Sept 18
    View PubMed
  3. Cogal AG, Ali AE, Arnous MG, Alhadi A, Zhou LT, Arroyo J, Seide BM, Rossler KJ, Reynolds LM, Kennedy GN, Elbarougy DE, Goldfarb DS, Milliner DS, Sas DJ, Lieske JC, Harris PC, Investigators of the Rare Kidney Stone Consortium. Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease. Clin J Am Soc Nephrol. 2025 Aug 12 [Epub ahead of print]
    View PubMed
  4. Michael M, Harvey E, Milliner DS, Frishberg Y, Sas DJ, Calle J, Copelovitch L, Penniston KL, Saland J, Somers MJG, Baum MA. Diagnosis and management of primary hyperoxalurias: best practices. Pediatr Nephrol. 2024 Nov; 39 (11):3143-3155 Epub 2024 May 16
    View PubMed
  5. Zaidan N, Wang C, Chen Z, Lieske JC, Milliner D, Seide B, Ho M, Li H, Ruggles KV, Modersitzki F, Goldfarb DS, Blaser M, Nazzal L. Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions. Kidney Int Rep. 2024 Jun; 9 (6):1836-1848 Epub 2024 Mar 11
    View PubMed
  6. Miao J, Mehta RA, Kattah A, Norby SM, Lieske JC, Milliner DS. Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases. Kidney Med. 2024 Jun; 6 (6):100824 Epub 2024 Apr 16
    View PubMed
  7. Sas DJ, Mara K, Mehta RA, Seide BM, Banks CJ, Danese DS, McGregor TL, Lieske JC, Milliner DS. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1. Pediatr Nephrol. 2024 Jan; 39 (1):141-148 Epub 2023 July 17
    View PubMed
  8. Langman CB, Assimos D, Blank M, Calle J, Grauer A, Kausz A, Milliner D, Nazzal L, Smith K, Tasian G, Thompson A, Wood KD, Worcester E, Yang S, Malley MA, Knauf F, Lieske JC, Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup). End Point Considerations for Clinical Trials in Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2023 Dec 1; 18 (12):1637-1644 Epub 2023 June 21
    View PubMed
  9. Genena KM, Sas DJ, Milliner DS, Lieske JC. Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant. Kidney Int Rep. 2023 Jul; 8 (7):1469-1472 Epub 2023 Mar 23
    View PubMed
  10. Arnous MG, Vaughan L, Mehta RA, Schulte PJ, Lieske JC, Milliner DS. Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria. J Urol. 2023 Jun; 209 (6):1141-1150 Epub 2023 Mar 08
    View PubMed
  11. Vaughan LE, Lieske JC, Milliner DS, Schulte PJ. Application of multivariate joint modeling of longitudinal biomarkers and time-to-event data to a rare kidney stone cohort. J Clin Transl Sci. 2023; 7 (1):e8 Epub 2022 Sept 26
    View PubMed
  12. Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal A, Harris PC, Milliner DS. Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci Rep. 2022 Sep 23; 12 (1):15886 Epub 2022 Sept 23
    View PubMed
  13. Singh P, Vaughan LE, Schulte PJ, Sas DJ, Milliner DS, Lieske JC. Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. Am J Kidney Dis. 2022 Sep; 80 (3):373-382 Epub 2022 Mar 16
    View PubMed
  14. Miao J, Mehta RA, Norby S, Seide B, Milliner DS, Lieske J, Kattah A. Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria. J Nephrol 2022 Jul; 35 (6):1771-1774 Epub 2022 Jan 18
    View PubMed
  15. Singh P, Viehman JK, Mehta RA, Cogal AG, Hasadsri L, Oglesbee D, Olson JB, Seide BM, Sas DJ, Harris PC, Lieske JC, Milliner DS. Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. Nephrol Dial Transplant. 2022 Apr 25; 37 (5):869-875
    View PubMed
  16. Hanna C, Potretzke TA, Chedid M, Rangel LJ, Arroyo J, Zubidat D, Tebben PJ, Cogal AG, Torres VE, Harris PC, Sas DJ, Lieske JC, Milliner DS, Chebib FT. Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Med. 2022 Mar; 4 (3):100419 Epub 2022 Jan 24
    View PubMed
  17. Cornell LD, Amer H, Viehman JK, Mehta RA, Lieske JC, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS, Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators. Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. Am J Transplant. 2022 Jan; 22 (1):85-95 Epub 2021 July 26
    View PubMed
  18. Singh P, Granberg CF, Harris PC, Lieske JC, Licht JH, Weiss A, Milliner DS. Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. Am J Kidney Dis. 2022 Jan; 79 (1):125-128 Epub 2021 July 07
    View PubMed
  19. Milliner DS, Lieske JC. Back to the Future: The Role of Metabolic Studies in Therapeutic Advances. J Am Soc Nephrol 2021 Dec 1; 32 (12):2980-2982 Epub 2021 Dec 01
    View PubMed
  20. Cogal AG, Arroyo J, Shah RJ, Reese KJ, Walton BN, Reynolds LM, Kennedy GN, Seide BM, Senum SR, Baum M, Erickson SB, Jagadeesh S, Soliman NA, Goldfarb DS, Beara-Lasic L, Edvardsson VO, Palsson R, Milliner DS, Sas DJ, Lieske JC, Harris PC, Investigators of the Rare Kidney Stone Consortium. Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney Int Rep. 2021 Nov; 6(11):2862-2884. Epub 2021 Sep 08.
    View PubMed
  21. Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol. 2021 Jul; 36 (7):1785-1793 Epub 2021 Jan 30
    View PubMed
  22. Frishberg Y, Deschenes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P, study collaborators. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021 Jul; 16 (7):1025-1036 Epub 2021 May 13
    View PubMed
  23. Hanna C, Potretzke TA, Cogal AG, Mkhaimer YG, Tebben PJ, Torres VE, Lieske JC, Harris PC, Sas DJ, Milliner DS, Chebib FT. High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney Int Rep. 2021 Jul; 6 (7):1895-1903 Epub 2021 May 12
    View PubMed
  24. Lorenz EC, Lieske JC, Seide BM, Olson JB, Mehta R, Milliner DS. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. Am J Kidney Dis. 2021 May; 77 (5):816-819 Epub 2020 Sept 04
    View PubMed
  25. Witting C, Langman CB, Assimos D, Baum MA, Kausz A, Milliner D, Tasian G, Worcester E, Allain M, West M, Knauf F, Lieske JC. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2021 Mar 08; 16(3):487-495. Epub 2020 Sep 08.
    View PubMed
  26. Singh P, Granberg CF, Harris PC, Lieske JC, Licht J, Weiss Andrew, Milliner DS. Primary Hyperoxaluria Type 3 can also result in End Stage Kidney Disease American Journal of Kidney Disease. 2021.
  27. Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, Lieske JC, Milliner DS. Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. Front Med (Lausanne). 2021; 8:592357 Epub 2021 Apr 09
    View PubMed
  28. Jayachandran M, Yuzhakov SV, Kumar S, Larson NB, Enders FT, Milliner DS, Rule AD, Lieske JC. Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. Orphanet J Rare Dis. 2020 Nov 11; 15 (1):319
    View PubMed
  29. Runolfsdottir HL, Palsson R, Agustsdottir IMS, Indridason OS, Li J, Dao M, Knebelmann B, Milliner DS, Edvardsson VO. Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency. Transplantation. 2020 Oct; 104 (10):2120-2128
    View PubMed
  30. Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC. End Points for Clinical Trials in Primary Hyperoxaluria. Clin J Am Soc Nephrol. 2020 Jul 1; 15 (7):1056-1065 Epub 2020 Mar 12
    View PubMed
  31. Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC. Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. Int J Mol Sci. 2020 May 20; 21 (10)
    View PubMed
  32. Wang X, Bhutani G, Vaughan LE, Enders FT, Haskic Z, Milliner D, Lieske JC, investigators of the Rare Kidney Stone Consortium. Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria. BMC Nephrol. 2020 Apr 15; 21 (1):133
    View PubMed
  33. Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, Lieske JC, investigators of the Rare Kidney Stone Consortium. Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. Pediatr Nephrol. 2020 Apr; 35 (4):633-640 Epub 2019 Mar 10
    View PubMed
  34. Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, Lieske JC. Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int. 2020 Apr; 97 (4):786-792 Epub 2019 Dec 13
    View PubMed
  35. Sas DJ, Harris PC, Milliner DS. Correction to: Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis. 2020 Feb; 48 (1):93
    View PubMed
  36. D'Costa MR, Winkler NS, Milliner DS, Norby SM, Hickson LJ, Lieske JC. Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient. Am J Kidney Dis. 2019 Sep; 74 (3):417-420 Epub 2019 Mar 22
    View PubMed
  37. Sas DJ, Harris PC, Milliner DS. Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis. 2019 Feb; 47 (1):79-89 Epub 2018 Dec 10
    View PubMed
  38. Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2018 Aug; 46 (4):313-323 Epub 2017 July 17
    View PubMed
  39. Fargue S, Milliner DS, Knight J, Olson JB, Lowther WT, Holmes RP. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria. J Am Soc Nephrol. 2018 Jun; 29 (6):1615-1623 Epub 2018 Mar 27
    View PubMed
  40. Dhondup T, Lorenz EC, Milliner DS, Lieske JC. Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. Am J Transplant. 2018 Jan; 18 (1):253-257 Epub 2017 Aug 14
    View PubMed
  41. Perinpam M, Enders FT, Mara KC, Vaughan LE, Mehta RA, Voskoboev N, Milliner DS, Lieske JC. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem. 2017 Dec; 50 (18):1014-1019 Epub 2017 July 29
    View PubMed
  42. Shellum JL, Nishimura RA, Milliner DS, Harper CM Jr, Noseworthy JH. Knowledge management in the era of digital medicine: A programmatic approach to optimize patient care in an academic medical center. Learn Health Syst. 2017 Apr; 1 (2):e10022 Epub 2017 Feb 13
    View PubMed
  43. Scheitel MR, Kessler ME, Shellum JL, Peters SG, Milliner DS, Liu H, Komandur Elayavilli R, Poterack KA, Miksch TA, Boysen J, Hankey RA, Chaudhry R. Effect of a Novel Clinical Decision Support Tool on the Efficiency and Accuracy of Treatment Recommendations for Cholesterol Management. Appl Clin Inform. 2017 Feb 8; 8 (1):124-136 Epub 2017 Feb 08
    View PubMed
  44. Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T. Genetic Risk Factors for Idiopathic Urolithiasis: A Systematic Review of the Literature and Causal Network Analysis. Eur Urol Focus. 2017 Feb; 3 (1):72-81 Epub 2017 May 19
    View PubMed
  45. Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC, Consensus Conference Group. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016 Dec; 29 (6):715-734 Epub 2016 July 25
    View PubMed
  46. Brooks ER, Hoppe B, Milliner DS, Salido E, Asplin JR, Rim J, Krevitt L, Olson J, Price HE, Vural G, Langman CB. Urine proteomics of primary hyperoxaluria type 1 reflect a profile of cell injury, inflammation, and extraosseous calcification inhibition American Journal of Nephrology. In press.
  47. Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, Chaiteerakij R, McCormick JB, Radulovic M, Graham RP, Torbenson MS, Tortorelli S, Scott CR, Lindor NM, Milliner DS, Oglesbee D, Al-Qabandi W, Grompe M, Gavrilov DK, El-Youssef M, Clark KJ, Atwal PS, Roberts LR, Klee EW, Ekker SC. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma. Hum Mutat. 2016 Oct; 37 (10):1097-105 Epub 2016 Aug 08
    View PubMed
  48. Mansoor CA, Jemshad A, Milliner DS, Bhushan NK. Bilateral nephrocalcinosis in primary hyperoxaluria type 1. Indian J Nephrol. 2016 Sep; 26 (5):383-384
    View PubMed
  49. Milliner DS. siRNA Therapeutics for Primary Hyperoxaluria: A Beginning. Mol Ther 2016 Apr; 24 (4):666-7
    View PubMed
  50. Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS, Investigators of Rare Kidney Stone Consortium. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol. 2016 Jan 7; 11 (1):119-26 Epub 2015 Dec 10
    View PubMed
  51. Brooks ER, Hoppe B, Milliner DS, Salido E, Rim J, Krevitt LM, Olson JB, Price HE, Vural G, Langman CB. Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. Am J Nephrol. 2016; 43: (4)293-303.
    View PubMed
  52. Shellum JL, Freimuth RR, Peters SG, Nishimura RA, Chaudhry R, Demuth SJ, Knopp AL, Miksch TA, Milliner DS. Knowledge as a Service at the Point of Care. AMIA Annu Symp Proc. 2016; 2016:1139-1148 Epub 2017 Feb 10
    View PubMed
  53. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone Consortium. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol. 2015 Oct; 26 (10):2559-70 Epub 2015 Feb 02
    View PubMed
  54. Milliner DS, Harris PC, Lieske JC. Primary Hyperoxaluria Type 3. GeneReviews® [Internet] Pagon RA, Adam MP, Ardinger HH, et al, editors Seattle (WA) University of Washington, Seattle 1993-2015 Available from: http://wwwncbinlmnihgov/books/NBK316514/.2015;
  55. Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG. Kidney stones are common after bariatric surgery. Kidney Int. 2015 Apr; 87 (4):839-45 Epub 2014 Oct 29
    View PubMed
  56. Carrasco A Jr, Granberg CF, Gettman MT, Milliner DS, Krambeck AE. Surgical management of stone disease in patients with primary hyperoxaluria. Urology. 2015 Mar; 85 (3):522-6
    View PubMed
  57. Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int. 2015 Mar; 87 (3):623-31 Epub 2014 Sept 17
    View PubMed
  58. Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve. 2015 Mar; 51 (3):449-54 Epub 2015 Jan 16
    View PubMed
  59. Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, Chaiteerakij R, McCormick JB, Radulovic M, Graham RP, Torbenson MS, Tortorelli S, Scott CR, Lindor NM, Milliner DS, Oglesbee D, Al-Qabandi W, Grompe M, Gavrilov DK, El-Youssef M, Clark KJ, Roberts LR, Klee EW, Ekker SC. Tyrosinemia Type I without Elevated Tyrosine or Succinylacetone. Submitted New England Journal of Medicine. 2015.
  60. Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant. 2014 Jun; 14 (6):1433-8 Epub 2014 May 02
    View PubMed
  61. Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol. 2014; 39 (5):376-82 Epub 2014 Apr 26
    View PubMed
  62. Nasr SH, Milliner DS, Wooldridge TD, Sethi S. Triamterene crystalline nephropathy. Am J Kidney Dis. 2014 Jan; 63(1):148-52. Epub 2013 Aug 16.
    View PubMed
  63. Shellum JL, Nishimura RA, Milliner DS, Harper CM, Wald JT, Noseworthy JH. Knowledge management in the era of a digital medicine: a programmatic approach to optimize patient care in an academic medical center. Journal of Academic Medicine. 2014.
  64. Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R. Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol. 2013 Oct; 28 (10):1923-42 Epub 2013 Jan 20
    View PubMed
  65. Lorenz EC, Michet CJ, Milliner DS, Lieske JC. Update on oxalate crystal disease. Curr Rheumatol Rep. 2013 Jul; 15 (7):340
    View PubMed
  66. Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck A, Sommers A, Phillips CL, Milliner D. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. Am J Physiol Renal Physiol. 2013; 305(11):F1574-84.
    View PubMed
  67. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012 Oct; 1822(10):1544-52. Epub 2012 Jul 05.
    View PubMed
  68. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol. 2012 Jul; 188 (1):247-52 Epub 2012 May 15
    View PubMed
  69. Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, Foreman JW, Chelminski PR, Kumar R. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab. 2012 Mar; 97(3):E423-7. Epub 2012 Feb 15.
    View PubMed
  70. Beara-Lasic L, Edvardsson VO, Palsson R, Lieske JC, Goldfarb DS, Milliner DS. Genetic causes of kidney stones and kidney failure. Clinical Reviews in Bone and Mineral Metabolism. 2012; 10(1):2-18.
  71. Monico CG, Milliner DS. Genetic determinants of urolithiasis. Nat Rev Nephrol. 2011 Dec 20; 8 (3):151-62
    View PubMed
  72. Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011 Nov; 26(11):3609-15. Epub 2011 Apr 02.
    View PubMed
  73. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011 Sep; 6(9):2289-95.
    View PubMed
  74. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, Milliner DS. Cardiac abnormalities in primary hyperoxaluria. Circ J. 2010 Nov; 74 (11):2403-9 Epub 2010 Sept 29
    View PubMed
  75. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS, IPHR Investigators. Transplantation outcomes in primary hyperoxaluria. Am J Transplant. 2010 Nov; 10 (11):2493-501 Epub 2010 Sept 17
    View PubMed
  76. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010 Sep 10; 87(3):392-9.
    View PubMed
  77. Nasr SH, Sethi S, Cornell LD, Milliner DS, Boelkins M, Broviac J, Fidler ME. Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. Nephrol Dial Transplant. 2010 Jun; 25(6):1909-15. Epub 2010 Jan 11.
    View PubMed
  78. Mookadam F, El Kheir M, Alharthi M, Mustafa S, Kazmier FJ, McBain R, Mookadam M, Tajik JA, Milliner DS. Vascular involvement in primary hyperoxalosis: an evidence based systematic overview over a fifty year span. Int J Nephrol Urol. 2010; 2(3):390-496.
  79. Swensen SJ, Dilling JA, Milliner DS, Zimmerman RS, Maples WJ, Lindsay ME, Bartley GB. Quality: the Mayo Clinic approach. Am J Med Qual. 2009 Sep-Oct; 24(5):428-40. Epub 2009 Jul 07.
    View PubMed
  80. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009 Jun; 75 (12):1264-1271 Epub 2009 Feb 18
    View PubMed
  81. Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation. 2009 Apr 27; 87 (8):1232-9
    View PubMed
  82. Monico CG, Weinstein A, Jiang Z, Rohlinger AL, Cogal AG, Bjornson BB, Olson JB, Bergstralh EJ, Milliner DS, Aronson PS. Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis. 2008 Dec; 52 (6):1096-103 Epub 2008 Oct 31
    View PubMed
  83. Ishitani M, Monico C, Milliner. Primary hyperoxaluria: new directions for diagnosis and treatment. Paediatrics and Child Health. 2008 Sep; 18(S1):54-6.
  84. Huang Y, Duncan AA, McKusick MA, Milliner DS, Bower TC, Kalra M, Gloviczki P, Hoskin TL. Renal artery intervention in pediatric and adolescent patients: a 20-year experience. Vasc Endovascular Surg. 2007 Dec-2008 Jan; 41(6):490-9.
    View PubMed
  85. Schwartz JJ, Ishitani MB, Weckwerth J, Morgenstern B, Milliner D, Stegall MD. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. Transplantation. 2007 Sep 27; 84(6):715-21.
    View PubMed
  86. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, Kumar R, Lieske JC. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007 Jul; 72: (1)100-7.
    View PubMed
  87. Monico CG, Rossetti S, Schwanz HA, Olson JB, Lundquist PA, Dawson DB, Harris PC, Milliner DS. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis. J Am Soc Nephrol. 2007 Jun; 18(6):1905-14. Epub 2007 Apr 25.
    View PubMed
  88. Knight J, Holmes RP, Milliner DS, Monico CG, Cramer SD. Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2. Nephrol Dial Transplant. 2006 Aug; 21(8):2292-5. Epub 2006 Apr 05.
    View PubMed
  89. Milliner DS. Stones, bones, and heredity. Acta Paediatr Suppl. 2006 Jul; 95 (452):27-30
    View PubMed
  90. Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore). 2006 Jan; 85 (1):1-21
    View PubMed
  91. Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005 Sep-Oct; 1(5):481-5. Epub 2005 Aug 26.
    View PubMed
  92. Ishitani MB, Milliner DS, Kim DY, Bohorquez HE, Heimbach JK, Sheedy PF 2nd, Morgenstern BZ, Gloor JM, Murphy JG, McBane RD, Bielak LF, Peyser PA, Stegall MD. Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant. 2005 Jul; 5 (7):1689-93
    View PubMed
  93. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005 May; 67 (5):1704-9
    View PubMed
  94. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS. International registry for primary hyperoxaluria. Am J Nephrol. 2005 May-Jun; 25 (3):290-6 Epub 2005 June 15
    View PubMed
  95. Milliner DS. The primary hyperoxalurias: An algorithm for diagnosis. Am J Nephrol 2005 Mar-Apr; 25(2):154-60.
    View PubMed
  96. Monico CG, Olson JB, Milliner DS. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol. 2005 Mar-Apr; 25(2):183-8. Epub 2005 Apr 21.
    View PubMed
  97. Jordan SC, Tyan D, Stablein D, Mcintosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J. Evaluation of intravenous immunoglobulin as are agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIHIG02 trial. J Am Soc Nephrol. 2004 Dec; 15(12):3256-62.
    View PubMed
  98. Pena de la Vega L, Lieske JC, Milliner D, Gonyea J, Kelly DG. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J Parenter Enteral Nutr. 2004 Nov-Dec; 28 (6):435-8
    View PubMed
  99. Kim DY, Stegall MD, Prieto M, Chow GK, Bohorquez HE, Covarrubias MA, Heimbach JK, Morgenstern BZ, Gloor JM, Milliner DS, Weckwerth JA, Weis KD, Ishitani MB. Hand-assisted laparoscopic donor nephrectomy for pediatric kidney allograft recipients. Pediatr Transplant. 2004 Oct; 8(5):460-3.
    View PubMed
  100. Norby SM, Milliner DS. Outcomes and complications of pregnancy in women with primary hyperoxaluria. Am J Kidney Dis. 2004 Feb; 43 (2):277-85
    View PubMed
  101. Charboneau JW, O'Loughlin MT, Milliner DS, Engen DE. Sonographically guided percutaneous radio frequency ablation of a renal cell carcinoma in a transplanted kidney. J Ultrasound Med. 2002 Nov; 21 (11):1299-302
    View PubMed
  102. Monico CG, Persson M, Ford GC, Rumsby G, Milliner DS. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int. 2002 Aug; 62(2):392-400.
    View PubMed
  103. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002 Mar; 30 (3):259-69 Epub 2002 Feb 04
    View PubMed
  104. Holmes RP, Assimos DG, Wilson DM, Milliner DS. (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1. BJU Int. 2001 Dec; 88(9):858-62.
    View PubMed
  105. Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 2001 Nov; 7(11):954-63.
    View PubMed
  106. Hogan MC, Gloor JM, Uhl JR, Cockerill FR, Milliner DS. Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection. Am J Kidney Dis. 2001 Oct; 38 (4):E22
    View PubMed
  107. Hassan I, Juncos LA, Milliner DS, Sarmiento JM, Sarr MG. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc. 2001 Jul; 76(7):758-60.
    View PubMed
  108. Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 2001 Jan; 59(1):31-6.
    View PubMed
  109. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. 2000 Jun; 105(6):1242-9.
    View PubMed
  110. Monico CG, Milliner DS. Hyperoxaluria and urolithiasis in young children: an atypical presentation. J Endourol. 1999 Nov; 13: (9)633-6.
    View PubMed
  111. Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet. 1999 Oct; 8(11):2063-9.
    View PubMed
  112. Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation. 1999 Jul 15; 68 (1):158-61
    View PubMed
  113. Milliner DS. Non-immune approaches to therapy. Pediatr Nephrol. 1998 Aug; 12(6):501-504.
  114. Milliner DS, Wilson DM, Smith LH. Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol. 1998 Mar-Apr; 11(Suppl 1):56-9.
  115. Waldo FB, Wyatt RJ, Hogg RJ, Andreoli SP, Milliner DS. Current concepts and controversies in IgA nephropathy. Pediatr Nephrol. 1998; 12(6):498-504.
    View PubMed
  116. Griffin MD, Gamble V, Milliner DS, Gomez MR, Harris PC, Torres VE. Neonatal presentation of autosomal dominant polycystic kidney disease with a maternal history of tuberous sclerosis. Nephrol Dial Transplant. 1997 Nov; 12 (11):2284-8
    View PubMed
  117. Dietzen DJ, Wilhite TR, Kenagy DN, Milliner DS, Smith CH, Landt M. Extraction of glyceric and glycolic acids from urine with tetrahydrofuran: utility in detection of primary hyperoxaluria. Clin Chem. 1997 Aug; 43(8 Pt 1):1315-20.
    View PubMed
  118. Husmann DA, Milliner DS, Segura JW. Ureteropelvic junction obstruction with concurrent renal pelvic calculi in the pediatric patient: a long-term followup. J Urol. 1996 Aug; 156 (2 Pt 2):741-3
    View PubMed
  119. Gloor JM, Ogburn PL Jr, Breckle RJ, Morgenstern BZ, Milliner DS. Urinary tract anomalies detected by prenatal ultrasound examination at Mayo Clinic Rochester. Mayo Clin Proc. 1995 Jun; 70 (6):526-31
    View PubMed
  120. Husmann DA, Milliner DS, Segura JW. Ureteropelvic junction obstruction with a simultaneous renal calculus: long-term followup. J Urol. 1995 May; 153: (5)1399-402.
    View PubMed
  121. Butani L, Rosekrans JA, Morgenstern BZ, Milliner DS. An unusual renal complication in a patient with osteogenesis imperfecta. Am J Kidney Dis. 1995 Mar; 25 (3):489-91
    View PubMed
  122. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med. 1994 Dec 8; 331(23):1553-8.
    View PubMed
  123. Williams AW, Morgenstern BZ, Murphy M, Milliner DS. Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. Pediatr Nephrol. 1994 Oct; 8 (5):566-9
    View PubMed
  124. Chlebeck PT, Milliner DS, Smith LH. Long-term prognosis in primary hyperoxaluria type II (L-glyceric aciduria). Am J Kidney Dis. 1994 Feb; 23 (2):255-9
    View PubMed
  125. Morgenstern BZ, Murphy M, Dayton J, Kokmen T, Purvis J, Milliner E, Sterioff S, Milliner D. Noncompliance in a pediatric renal transplant population. Transplant Proc. 1994 Feb; 26(1):129.
    View PubMed
  126. Morgenstern BZ, Murphy M, Milliner DS. Interaction of lipids and cyclosporine. Transplant Proc. 1994 Feb; 26(1):130.
    View PubMed
  127. Milliner DS, Morgenstern BZ, Murphy M, Gonyea J, Sterioff S. Lipid levels following renal transplantation in pediatric recipients. Transplant Proc. 1994 Feb; 26(1):112-4.
    View PubMed
  128. Morgenstern BZ, Milliner DS, Murphy ME, Simmons PS, Moyer TP, Wilson DM, Smith LH. Urinary oxalate and glycolate excretion patterns in the first year of life: a longitudinal study. J Pediatr. 1993 Aug; 123 (2):248-51
    View PubMed
  129. Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc. 1993 Mar; 68 (3):241-8
    View PubMed
  130. Argueso LR, Ritchey ML, Boyle ET Jr, Milliner DS, Bergstralh EJ, Kramer SA. Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol. 1992 Sep; 6 (5):412-6
    View PubMed
  131. Argueso LR, Ritchey ML, Boyle ET Jr, Milliner DS, Bergstralh EJ, Kramer SA. Prognosis of children with solitary kidney after unilateral nephrectomy. J Urol. 1992 Aug; 148 (2 Pt 2):747-51
    View PubMed
  132. Morgenstern BZ, Milliner DS, Debernardi M, Schniepp B. Peritoneal dialysis prescription and protein catabolic rates in children with acute renal failure. Int Congr Ser. 1992; 947:654-659.
  133. Milliner DS, Morgenstern BZ. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 1991 Sep; 5 (5):587-90
    View PubMed
  134. Milliner DS. Cystinuria. Endocrinology & Metabolism Clinics of North America. 1990 Dec; 19(4):889-907.
    View PubMed
  135. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990 Nov; 38 (5):931-6
    View PubMed
  136. McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med. 1990 Mar; 74(275):257-76.
    View PubMed
  137. Milliner DS. When and how should deferoxamine be used in chronic dialysis. Seminars in Dialysis. 1990; 3:15-8.
  138. McCarthy JT, Milliner DS, Schmidt DF, Schniepp BJ, Kurtz SB, Johnson WJ. Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients. Kidney Int. 1988 Dec; 34 (6):804-8
    View PubMed
  139. Ten RM, Torres VE, Milliner DS, Schwab TR, Holley KE, Gleich GJ. Acute interstitial nephritis: immunologic and clinical aspects. Mayo Clin Proc. 1988 Sep; 63 (9):921-30
    View PubMed
  140. Rakela J, Kurtz SB, McCarthy JT, Krom RA, Baldus WP, McGill DB, Perrault J, Milliner DS. Postdilution hemofiltration in the management of acute hepatic failure: a pilot study. Mayo Clin Proc. 1988 Feb; 63 (2):113-8
    View PubMed
  141. Milliner DS, Malekzadeh M, Lieberman E, Coburn JW. Plasma aluminum levels in pediatric dialysis patients: comparison of hemodialysis and continuous ambulatory peritoneal dialysis. Mayo Clin Proc. 1987 Apr; 62(4):269-74.
    View PubMed
  142. McCarthy JT, Milliner DS, Kurtz SB, Johnson WJ, Moyer TP. Interpretation of serum aluminum values in dialysis patients. Am J Clin Pathol. 1986 Nov; 86(5):629-36.
    View PubMed
  143. Milliner DS, Lieberman E, Landing BH. Pulmonary calcinosis after renal transplantation in pediatric patients. Am J Kidney Dis. 1986 Jun; 7(6):495-501.
    View PubMed
  144. Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW. Clearance of aluminum by hemodialysis: Effect of desferrioxamine. Kidney Int. 1986; 29(Supp.18):100-3.
  145. Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW. Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int. 1986; 29(Supp.18):96-9.
  146. Ott SM, Andress DL, Nebeker HG, Milliner DS, Maloney NA, Coburn JW, Sherrard DJ. Changes in bone histology after treatment with desferrioxamine. Kidney Int. 1986; 29(Supp.18):108-13.
    View PubMed
  147. Milliner DS, Shinaberger JH, Shuman P, Coburn JW. Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. N Engl J Med. 1985; 312:165-7.
    View PubMed
  148. Norris KC, Crooks PW, Nabeker HG, Hercz G, Milliner DS, Gerszi K, Slatopolsky E, Andress DL, Sherrard DJ, Coburn JW. Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and "epidemic" forms of the syndrome. Am J Kidney Dis. 1985; 6:342-7.
    View PubMed
  149. Milliner DS, Nebeker HG, Ott SM, Andress DL, Sherrard DJ, Alfrey AC, Slatopolsky EA, Coburn JW. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med. 1984 Dec; 101(6):775-9.
    View PubMed
  150. Milliner DS, Pierides AM, Holley KE. Renal transplantation in Alport's syndrome: anti-glomerular basement membrane glomerulonephritis in the allograft. Mayo Clin Proc. 1982 Jan; 57(1):35-43.
    View PubMed